Mauna Kea sp increased nearly 10% yesterday, probably on the back of this which will help when Optiscan are in a position to offer the flexible probe for partnering.
Mauna Kea Technologies Announces a Significant Increase in the Reimbursement of Optical Endomicroscopy in the United States, the Centers for Medicare and Medicaid Services (CMS) CPT 43252).
The final scale provides for a 131% increase in the reimbursement rate for procedures referred to under CPT code 43252 for hospital procedures, and 86% for procedures performed in ambulatory surgery centers.
According to Mauna Kea's internal estimates, five million upper gastrointestinal endoscopies performed annually in the United States could clinically benefit from the use of Cellvizio.
'These new rates considerably reinforce the economic argument for adopting Cellvizio as a standard of care for institutions,' says Sacha Loiseau, founder and CEO of Mauna Kea.
https://www.abcbourse.com/forums/msg558616_que-vaut-mauna-kea-perspectives-2017.aspx
https://www.euronext.com/en/products/equities/FR0010609263-XPAR/quotes
Mauna Kea sp increased nearly 10% yesterday, probably on the...
Add to My Watchlist
What is My Watchlist?
